Abstract
Community-associated methicillin resistant Staphylococcus aureus (CAMRSA) infections are increasing. Although gentamicin (GEN) is usually susceptible against CA-MRSA, GEN is rarely considered for treatment as monotherapy. We employed an in vitro pharmacodynamic model (IVPDM) to compare efficacies of GEN against CA-MRSA with two dosing regimens [thrice-daily (TD), once-daily (OD)]. Using two strains of CA-MRSA, we adopted IVPDM comprised of two-compartments with a surface-to-volume ratio of 5.34 cm(-1). GEN regimens were simulated with human pharmacokinetic data of TD and OD. Experiments were performed over 48 hours in triplicate for each strain and dosing regimen. MICs of GEN for YSSA1 and YSSA15 were 1 and 2 mg/L, respectively. In OD, indices of peak/MIC were > 8.6 at least, in contrast to < 6.4 in TD. A > or = 3-log(10) reduction in CFU/mL was demonstrated prior to 4 hours in TD and OD, and continued until 8 hours for both strains. However, reductions in the colony counts at 24 and 48 hours were significantly larger for OD compared to TD in both strains (p < 0.001). During TD, resistance developed in YSSA1 and small colony variants (SCVs) were documented in YSSA15. No resistance or SCVs were observed during OD in both strains...Continue Reading
References
Sep 1, 1992·Antimicrobial Agents and Chemotherapy·M L BarclayS T Chambers
Jul 1, 1987·Antimicrobial Agents and Chemotherapy·J BlaserS H Zinner
Sep 1, 1993·Antimicrobial Agents and Chemotherapy·B J McGrathM J Rybak
Nov 26, 1997·Antimicrobial Agents and Chemotherapy·H H HoulihanM J Rybak
Jul 2, 1999·Antimicrobial Agents and Chemotherapy·M J RybakG L Drusano
Mar 27, 2001·The Journal of Antimicrobial Chemotherapy·M C DomínguezM V Borobio
Jan 18, 2002·Antimicrobial Agents and Chemotherapy·Joan GavaldàAlbert Pahissa
Oct 18, 2002·Antimicrobial Agents and Chemotherapy·Charles R BonapaceRoger L White
Jan 14, 2003·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Nicole BaumertHans-Georg Sahl
Nov 26, 2003·Antimicrobial Agents and Chemotherapy·Dong-Gun LeeMoon-Won Kang
Jan 9, 2004·Infectious Disease Clinics of North America·John Turnidge
Jan 17, 2004·Lancet·Philippe Moreillon, Yok-Ai Que
Feb 6, 2004·International Journal of Medical Microbiology : IJMM·Franziska SchaaffHans-Georg Sahl
Sep 25, 2004·Antimicrobial Agents and Chemotherapy·Samuel A ShelburneRichard J Hamill
Nov 24, 2004·International Journal of Antimicrobial Agents·Wendy J MunckhofJohn D Turnidge
Mar 16, 2005·Pharmacotherapy·Michael J Rybak, Kerry L LaPlante
Apr 9, 2005·The New England Journal of Medicine·Scott K FridkinUNKNOWN Active Bacterial Core Surveillance Program of the Emerging Infections Program Network
Apr 28, 2005·The Lancet Infectious Diseases·Nicola ZetolaWilliam R Bishai
Mar 17, 2006·Nature Reviews. Microbiology·Richard A ProctorGeorg Peters
May 3, 2006·Injury·Christof von EiffKarsten Becker
May 17, 2006·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·G KahlmeterO Stetsiouk
Jun 1, 2006·The Journal of Antimicrobial Chemotherapy·Jeremy A SchaferJohn C Rotschafer
Jul 28, 2006·Antimicrobial Agents and Chemotherapy·Vincent H TamElizabeth A Coyle
Sep 20, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Parham SendiWerner Zimmerli
Feb 16, 2007·Diagnostic Microbiology and Infectious Disease·Brian T TsujiGlenn W Kaatz
Oct 19, 2007·Journal of Clinical Microbiology·Chulmin ParkBok Yang Pyun
Dec 25, 2007·The Korean journal of laboratory medicine·Heungsup SungGin Hyug Lee